What is Leerink Partnrs' Estimate for MNMD Q1 Earnings?

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Mind Medicine (MindMed) in a research note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman expects that the company will earn ($0.35) per share for the quarter. The consensus estimate for Mind Medicine (MindMed)'s current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Mind Medicine (MindMed)'s Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.47) EPS and FY2028 earnings at ($1.65) EPS.

MNMD has been the topic of a number of other research reports. HC Wainwright reiterated a "buy" rating and issued a $55.00 price target on shares of Mind Medicine (MindMed) in a research report on Friday, March 7th. Evercore ISI assumed coverage on shares of Mind Medicine (MindMed) in a research report on Tuesday, January 28th. They set an "outperform" rating and a $23.00 price target on the stock. Finally, Robert W. Baird dropped their price objective on Mind Medicine (MindMed) from $27.00 to $16.00 and set an "outperform" rating on the stock in a research note on Friday, March 7th. Ten equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $25.11.

Mind Medicine (MindMed) Trading Down 1.0 %

NASDAQ MNMD traded down $0.06 on Wednesday, hitting $5.71. The company's stock had a trading volume of 276,546 shares, compared to its average volume of 1,392,522. The company has a quick ratio of 9.00, a current ratio of 9.00 and a debt-to-equity ratio of 0.09. Mind Medicine has a 1-year low of $4.70 and a 1-year high of $10.44. The firm has a market cap of $430.35 million, a PE ratio of -2.53 and a beta of 2.54. The company's 50-day moving average is $6.54 and its 200 day moving average is $6.91.

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last posted its earnings results on Thursday, March 6th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.08). During the same quarter in the previous year, the company posted ($0.59) earnings per share.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. AWM Investment Company Inc. raised its position in shares of Mind Medicine (MindMed) by 39.9% in the fourth quarter. AWM Investment Company Inc. now owns 1,193,162 shares of the company's stock worth $8,304,000 after buying an additional 340,162 shares in the last quarter. Marshall Wace LLP increased its position in shares of Mind Medicine (MindMed) by 9.3% in the fourth quarter. Marshall Wace LLP now owns 2,501,391 shares of the company's stock worth $17,410,000 after purchasing an additional 213,526 shares during the last quarter. Tang Capital Management LLC purchased a new stake in Mind Medicine (MindMed) in the fourth quarter valued at approximately $1,392,000. Geode Capital Management LLC lifted its position in Mind Medicine (MindMed) by 10.8% during the third quarter. Geode Capital Management LLC now owns 1,677,702 shares of the company's stock valued at $9,548,000 after purchasing an additional 162,933 shares during the last quarter. Finally, Allostery Investments LP bought a new position in shares of Mind Medicine (MindMed) in the 4th quarter worth $905,000. Institutional investors own 27.91% of the company's stock.

Insider Activity at Mind Medicine (MindMed)

In related news, CEO Robert Barrow sold 21,208 shares of the stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total transaction of $142,941.92. Following the completion of the transaction, the chief executive officer now owns 856,556 shares in the company, valued at approximately $5,773,187.44. This represents a 2.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Daniel Karlin sold 6,836 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total value of $46,074.64. Following the completion of the transaction, the insider now owns 446,177 shares in the company, valued at approximately $3,007,232.98. The trade was a 1.51 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,391 shares of company stock valued at $204,835. 2.26% of the stock is owned by corporate insiders.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.